Recognize risks. Understanding interrelations.

The General Concept of BeLOVE

The Berlin Longterm Observation of Vascular Events Study (BeLOVE) is an observational clinical cohort study of patients with existing cardiovascular disease (including acute coronary syndrome, stroke, heart failure, acute kidney injury), or type 2 diabetes, who have a very high risk of future cardiovascular events. Patients are enrolled on occasion of an acute event in association with hospitalisation at Charité or with long-standing diabetes in a joint effort of primarily four disciplines: neurology, cardiology, endocrinology and nephrology.




The aim of BeLOVE to improve short- and long-term prediction and mechanistic understanding of cardiovascular disease progression and outcomes in these very high risk patients, both in the acute as well as in the chronic phase, in order to provide the basis for improved, individualized management.


Cardiovascular disease (CVD) is the leading cause of premature death worldwide with multiple forms of organ dysfunction, comorbidities, impaired health-related quality of life as well as frailty and dependency in the elderly. Patients experiencing an acute vascular event are at very high risk for subsequent events affecting the same or other organs. This patient group has a heavy disease burden and consumes a large proportion of health care resources. However, despite the overall poor prognosis, individual courses are highly variable, suggesting a yet poorly understood complexity of the underlying pathomechanisms that determine either recovery and stabilization or Progression.


The BeLOVE Study willstudy this high-risk patient group in an innovative, interdisciplinary research concept. In total, 10.000 patients, the majority of which are hospitalized at Charité, will be included acutely with an index event due to acute coronary syndrome (ACS), acute heart failure (AHF), acute cerebrovascular disorder (stroke/TIA), or acute kidney injury (AKI) together with a high-risk group of patients with diabetes (T2DM) (one cohort- five disease entities).

Patients will be thoroughly phenotyped directly following the index event and then after both 90 days and 2 years of follow-up. Planned maximal followed for up is 10 years.




BeLOVE is fully embedded in the existing infrastructure of the Charite Universitätsmedizin Berlin, the Core Facilities of the BIH including the Clinical Research Unit (CRU) as well as the Max-Delbrück-Center for Molecular Medicine (MDC). At the same time, BeLOVE can serve as a use case for many projects in the field of infrastructure development and thus form the basis for further translational research projects.